Silver Book Fact

Cost-effectiveness of TAVR in sSAS patients

Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY gained and $43,114 per life-year (LY) gained.

Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. JACC. 2016; 67(1): 29-38. http://www.onlinejacc.org/content/67/1/29

Reference

Title
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
Publication
JACC
Publication Date
2016
Volume & Issue
Volume 67, Issue 1
Pages
29-38
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Undertreatment of patients with sSAS
    AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on.  
  • TAVR Procedures 2011 – 2015
    From approval in 2011 through 2015, >54,000 transcatheter aortic valve replacements (TAVRs) were performed in 418 centers in 48 states.